James F. White
Keine laufenden Positionen mehr
Karriereverlauf von James F. White
Ehemalige bekannte Positionen von James F. White
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - | - |
| COLUCID PHARMACEUTICALS INC | Gründer | 01.01.2005 | - |
| Präsident | 25.10.2006 | - | |
Hypnion, Inc.
 Hypnion, Inc. Miscellaneous Commercial ServicesCommercial Services Hypnion, Inc. discovered and developed neuroscience drugs. It focused on the development of novel therapeutics for the treatment of central nervous system disorders to serve the underserved markets of sleep and wake-alertness disorders and circadian rhythm abnormalities. The company was founded in 2000 and was headquartered in Lexington, MA. | Geschäftsführer | 29.07.2009 | - |
| Corporate Officer/Principal | 01.01.2001 | 29.07.2009 |
Ausbildung von James F. White
| Purdue University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Operating Officer | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Hypnion, Inc.
Hypnion, Inc. Miscellaneous Commercial ServicesCommercial Services Hypnion, Inc. discovered and developed neuroscience drugs. It focused on the development of novel therapeutics for the treatment of central nervous system disorders to serve the underserved markets of sleep and wake-alertness disorders and circadian rhythm abnormalities. The company was founded in 2000 and was headquartered in Lexington, MA. | Commercial Services |
CoLucid Pharmaceuticals, Inc.
 CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- James F. White
- Erfahrung